知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

27 records (took 0.049 seconds)

    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
    2.
    发明申请
    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
    识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20090010939A1

    公开(公告)日：2009-01-08

    申请号：US11840593

    申请日：2007-08-17

    Applicant: Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    Inventor： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC: C07K16/18

    CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    Abstract translation: 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
    3.
    发明申请
    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
    识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20080114156A1

    公开(公告)日：2008-05-15

    申请号：US11840594

    申请日：2007-08-17

    Applicant: Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    Inventor： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC: C07K16/28

    CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    Abstract translation: 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies
    5.
    发明授权
    Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies 失效
    用7C10和16C10 CD80特异性抗体治疗类风湿关节炎的方法

    公开(公告)号：US07510712B2

    公开(公告)日：2009-03-31

    申请号：US11840593

    申请日：2007-08-17

    Applicant: Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    Inventor： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC: A61K39/395 ,  C07K16/28

    CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    Abstract translation: 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
    10.
    发明授权
    Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies 失效
    通过施用7C10和16C10 CD80特异性抗体诱导免疫抑制的方法

    公开(公告)号：US07510713B2

    公开(公告)日：2009-03-31

    申请号：US11840597

    申请日：2007-08-17

    Applicant: Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    Inventor： Darrell R. Anderson ,  Nabil Hanna ,  Peter Brams

    IPC: A61K39/395 ,  C07K16/28

    CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    Abstract translation: 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

Patent Agency Ranking